报价延迟最少15分钟:2026/08/31 22:22 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.93 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.31/-0.13
|
|
企业价值
75.47M
|
| 资产负债 |
|
每股账面净值
0.20
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
1.12M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy. |
